Pfizer Inc. (NYSE:PFE) is included among the Dividend Champions, Contenders, and Challengers List: 15 Highest Yielding Stocks ...

Pfizer Inc. delivered a 17% total return since early November, but fundamentals lag and valuation isn’t compelling. Read more on PFE stock here.

PFE stock decreased 30.0% from a peak of $40.71 on January 23, 2020, to $28.49 on March 23, 2020, compared to a ...

Pfizer (PFE) chairman and CEO Albert Bourla joins Julie Hyman on Market Domination to talk more about the pharmaceutical ...

The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030. As a result, many top healthcare companies are vying for a ...

Pharmaceutical giant Pfizer (PFE) released its fourth quarter earnings results that topped Wall Street's expectations on its top and bottom lines. The stock is coming under some pressure on Tuesday ...

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

In lieu of a Super Bowl ad this year, Pfizer has unveiled a year-long cancer campaign that aims to encourage screening.

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.

As 2025 results reveal a mixed year for Pfizer, the company is looking to turn its fortunes around with newly acquired Metsera's obesity assets.

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...

Entera Bio Ltd. (NASDAQ:ENTX) has appointed seasoned pharmaceutical executive Geno J. Germano as Chairman of the Board, effective February 4, 2026, as the company approaches several key clinical ...